These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25762593)

  • 1. CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.
    Dreja H; Pade C; Chen L; McKnight Á
    J Gen Virol; 2015 Jul; 96(Pt 7):1899-905. PubMed ID: 25762593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
    Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
    Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
    Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
    J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.
    Wang W; Zirkle B; Nie J; Ma J; Gao K; Chen XS; Huang W; Kong W; Wang Y
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):270-7. PubMed ID: 25751231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
    Duan H; Chen X; Boyington JC; Cheng C; Zhang Y; Jafari AJ; Stephens T; Tsybovsky Y; Kalyuzhniy O; Zhao P; Menis S; Nason MC; Normandin E; Mukhamedova M; DeKosky BJ; Wells L; Schief WR; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2018 Aug; 49(2):301-311.e5. PubMed ID: 30076101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
    J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
    Moody MA; Gao F; Gurley TC; Amos JD; Kumar A; Hora B; Marshall DJ; Whitesides JF; Xia SM; Parks R; Lloyd KE; Hwang KK; Lu X; Bonsignori M; Finzi A; Vandergrift NA; Alam SM; Ferrari G; Shen X; Tomaras GD; Kamanga G; Cohen MS; Sam NE; Kapiga S; Gray ES; Tumba NL; Morris L; Zolla-Pazner S; Gorny MK; Mascola JR; Hahn BH; Shaw GM; Sodroski JG; Liao HX; Montefiori DC; Hraber PT; Korber BT; Haynes BF
    Cell Host Microbe; 2015 Sep; 18(3):354-62. PubMed ID: 26355218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
    Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
    J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.
    Cheng HD; Grimm SK; Gilman MS; Gwom LC; Sok D; Sundling C; Donofrio G; Karlsson Hedestam GB; Bonsignori M; Haynes BF; Lahey TP; Maro I; von Reyn CF; Gorny MK; Zolla-Pazner S; Walker BD; Alter G; Burton DR; Robb ML; Krebs SJ; Seaman MS; Bailey-Kellogg C; Ackerman ME
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.